Subsequent Indications Clause Samples
The "Subsequent Indications" clause defines how additional instructions, requests, or directions provided after the initial agreement are to be handled between the parties. Typically, this clause outlines the process for submitting and acknowledging such subsequent indications, specifying whether they must be in writing, who is authorized to issue them, and how they become binding. Its core practical function is to ensure that any changes or additions to the original agreement are managed in an orderly and documented manner, thereby reducing misunderstandings and disputes over later communications.
Subsequent Indications. Orchard may, at any time, request that an additional indication ([***]) be included in this Agreement and the following provisions shall apply:
(a) Orchard may by written notice to BioMedica received on or before [***], nominate [***] and upon [***], such indication shall become a Subsequent Indication; and/or
(b) Orchard may, at any time after [***], request [***] and, if [***], such additional indication shall become a Subsequent Indication.
Subsequent Indications. Astellas shall not be obligated to make any milestone payments with respect to Marketing Approval for the fourth and subsequent indications of the Compound and/or Product. It is understood that, for purposes of this Section 6.2.7, a single MAA or Marketing Approval may include more than one indication, e.g. both the first and second indications, or the second and third indications, as the case may be.
Subsequent Indications. Milestone payments shall be paid as set forth in Section 7.02(a) upon the first achievement of each milestone event for each of the First Indication, Second Indication, Third Indication and Fourth Indication. No amounts shall be due for subsequent or repeated achievement of such milestone by the same Licensed Product for additional Indications beyond the Fourth Indication. The total milestone payments payable under Section 7.02(a) shall not exceed forty million five hundred thousand U.S. dollars ($40,500,000.00). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.
Subsequent Indications. Milestone payments shall be paid as set forth in Section 7.02(a) upon the first achievement of each milestone event for each of [***]. No amounts shall be due for subsequent or repeated achievement of such milestone by the same Licensed Product for additional Indications beyond the Fourth Indication. The total milestone payments payable under Section 7.02(a) shall not exceed [***] per Licensed Product to Merck and [***] per Licensed Product to Cerecor.